https://www.selleckchem.com/pr....oducts/sacituzumab-g
01) and major (P .01) complications, a higher rate of reoperation (P .01), and a higher rate of unplanned readmissions (P .01). Finally, the cohort with metastatic cancer had a higher rate of postoperative 30-day mortality (P .01) than patients without metastatic cancer. Patients undergoing a CN have significantly worse perioperative outcomes than patients undergoing a radical nephrectomy without evidence of metastases. Careful surgical risk stratification and appropriate patient counseling should be undert
Like
Comment
Share
